Baird Maintains Outperform on Regenxbio, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 89.6%

Neg 0% Neu 0% Pos 89.6%

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $27 to $32.